Rocket Pharmaceuticals said it received $180 million from the sale of a rare pediatric disease priority review voucher tied to the accelerated FDA approval of Kresladi in March. Rocket described the non-dilutive proceeds as funding a pipeline that includes a gene therapy in pivotal clinical testing for Danon disease. Priority review vouchers can materially change near-term financing flexibility for small biotechs because they convert regulatory progress into capital without immediate equity dilution. Rocket’s use of the voucher proceeds underscores how accelerated approvals continue to drive investment into late-stage and pivotal programs.